| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807135 | LIFE MOLECULAR | Stilbene derivatives and their use for binding and imaging amyloid plaques |
Mar, 2029
(5 years from now) | |
Neuraceq is owned by Life Molecular.
Neuraceq contains Florbetaben F-18.
Neuraceq has a total of 1 drug patent out of which 0 drug patents have expired.
Neuraceq was authorised for market use on 19 March, 2014.
Neuraceq is available in solution;intravenous dosage forms.
Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.
The generics of Neuraceq are possible to be released after 18 March, 2029.
Drugs and Companies using FLORBETABEN F-18 ingredient
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
NEURACEQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic